Patents by Inventor Jonathan W. Lockner

Jonathan W. Lockner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11891392
    Abstract: There are disclosed imidazolinopyrimidinone compounds that have activity to induce TRAIL gene expression in macrophages. There is further disclosed a method for treating various cancers comprising administering effective amounts of an imidazolinopyrimidinone having the structure of Formula I herein.
    Type: Grant
    Filed: July 12, 2021
    Date of Patent: February 6, 2024
    Assignee: The Scripps Research Institute
    Inventors: Kim D. Janda, Nicholas T. Jacob, Jonathan W. Lockner
  • Publication number: 20220002300
    Abstract: There are disclosed imidazolinopyrimidinone compounds that have activity to induce TRAIL gene expression in macrophages. There is further disclosed a method for treating various cancers comprising administering effective amounts of an imidazolinopyrimidinone having the structure of Formula I herein.
    Type: Application
    Filed: July 12, 2021
    Publication date: January 6, 2022
    Inventors: Kim D. JANDA, Nicholas T. JACOB, Jonathan W. LOCKNER
  • Publication number: 20200283440
    Abstract: There are disclosed imidazolinopyrimidinone compounds that have activity to induce TRAIL gene expression in macrophages. There is further disclosed a method for treating various cancers comprising administering effective amounts of an imidazolinopyrimidinone having the structure of Formula I herein.
    Type: Application
    Filed: April 14, 2020
    Publication date: September 10, 2020
    Applicant: THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Kim D. JANDA, Nicholas T. JACOB, Jonathan W. LOCKNER
  • Patent number: 10633385
    Abstract: There are disclosed imidazolinopyrimidinone compounds that have activity to induce TRAIL gene expression in macrophages. There is further disclosed a method for treating various cancers comprising administering effective amounts of an imidazolinopyrimidinone having the structure of Formula I herein.
    Type: Grant
    Filed: March 20, 2019
    Date of Patent: April 28, 2020
    Assignee: THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Kim D. Janda, Nicholas T. Jacob, Jonathan W. Lockner
  • Patent number: 10487141
    Abstract: The invention provides chiral haptens (?)-3?-AmNic and (?)-N4N for use in generating antibodies in a patient specific for (?)-nicotine. The haptens can be conjugated to suitable carrier proteins and administered as an antigenic mixture, optionally comprising adjuvant(s), to a patient suffering from nicotine or tobacco addiction or habituation.
    Type: Grant
    Filed: December 10, 2018
    Date of Patent: November 26, 2019
    Assignee: The Scripps Research Institute
    Inventors: Kim D. Janda, Jonathan W. Lockner
  • Publication number: 20190284188
    Abstract: There are disclosed imidazolinopyrimidinone compounds that have activity to induce TRAIL gene expression in macrophages. There is further disclosed a method for treating various cancers comprising administering effective amounts of an imidazolinopyrimidinone having the structure of Formula I herein.
    Type: Application
    Filed: March 20, 2019
    Publication date: September 19, 2019
    Inventors: Kim D. Janda, Nicholas T. Jacob, Jonathan W. Lockner
  • Publication number: 20190119363
    Abstract: The invention provides chiral haptens (?)-3?-AmNic and (?)-N4N for use in generating antibodies in a patient specific for (?)-nicotine. The haptens can be conjugated to suitable carrier proteins and administered as an antigenic mixture, optionally comprising adjuvant(s), to a patient suffering from nicotine or tobacco addiction or habituation.
    Type: Application
    Filed: December 10, 2018
    Publication date: April 25, 2019
    Inventors: Kim D. Janda, Jonathan W. Lockner
  • Patent number: 10239877
    Abstract: There are disclosed imidazolinopyrimidinone compounds that have activity to induce TRAIL gene expression in macrophages. There is further disclosed a method for treating various cancers comprising administering effective amounts of an imidazolinopyrimidinone having the structure of Formula I herein. The invention is directed, in various embodiments, to a compound and pharmaceutical composition comprising an effective amount of a compound capable of inducing expression of TRAIL gene in cells capable of expressing the TRAIL gene to produce the cytokine TRAIL.
    Type: Grant
    Filed: March 30, 2015
    Date of Patent: March 26, 2019
    Assignee: The Scripps Research Institute
    Inventors: Kim D. Janda, Nicholas T. Jacob, Jonathan W. Lockner
  • Publication number: 20180086820
    Abstract: The invention provides chiral haptens (?)-3?-AmNic and (?)-N4N for use in generating antibodies in a patient specific for (?)-nicotine. The haptens can be conjugated to suitable carrier proteins and administered as an antigenic mixture, optionally comprising adjuvant(s), to a patient suffering from nicotine or tobacco addiction or habituation.
    Type: Application
    Filed: November 21, 2017
    Publication date: March 29, 2018
    Inventors: Kim D. Janda, Jonathan W. Lockner
  • Publication number: 20170107275
    Abstract: The invention provides chiral haptens (?)-3?-AmNic and (?)-N4N for use in generating antibodies in a patient specific for (?)-nicotine. The haptens can be conjugated to suitable carrier proteins and administered as an antigenic mixture, optionally comprising adjuvant(s), to a patient suffering from nicotine or tobacco addiction or habituation.
    Type: Application
    Filed: May 19, 2015
    Publication date: April 20, 2017
    Inventors: Kim D. JANDA, Jonathan W. LOCKNER
  • Publication number: 20170107221
    Abstract: There are disclosed imidazolinopyrimidinone compounds that have activity to induce TRAIL gene expression in macrophages. There is further disclosed a method for treating various cancers comprising administering effective amounts of an imidazolinopyrimidinone having the structure of Formula I herein. The invention is directed, in various embodiments, to a compound and pharmaceutical composition comprising an effective amount of a compound capable of inducing expression of TRAIL gene in cells capable of expressing the TRAIL gene to produce the cytokine TRAIL.
    Type: Application
    Filed: March 30, 2015
    Publication date: April 20, 2017
    Inventors: Kim D. Janda, Nicholas T. Jacob, Jonathan W. Lockner